Akt and phospholipase Cγ are involved in the regulation of growth and migration of MDA-MB-468 breast cancer and SW480 colon cancer cells when cultured with diabetogenic levels of glucose and insulin

BMC Research Notes

Kurt S Zänker¹  Bernd Niggemann¹  Jonas C Piecha¹  Kai Masur²  Nicola M Tomas¹ 

[1] Institute of Immunology and Experimental Oncology, Witten/Herdecke University, Stockumer Str. 10, D-58448, Witten, Germany;Institute for Plasma Research and Technology e.V. – INP Greifswald, Felix-Hausdorff-Str. 2, D-17489, Greifswald, Germany

关键词: PLCγ;    Akt;    Insulin;    Glucose;    Diabetes mellitus type 2;    Breast and colon cancer;   

Others  :  1166462
DOI  :  10.1186/1756-0500-5-214

 received in 2012-01-05, accepted in 2012-05-03,  发布年份 2012

【 摘 要 】

Background

Epidemiological studies revealed a strong correlation between the metabolic syndrome/diabetes mellitus type 2 (DM2) and higher incidence and faster progression of breast and colon cancer. However, the underlying molecular mechanisms are widely unknown. Akt and phospholipase Cγ (PLCγ) are involved in tyrosine kinase signaling and promote tumor cell growth and migration. Therefore, we examined regulatory functions and expression of Akt and PLCγ in a simplified in vitro diabetogenic model.

Findings

Protein expression was determined by western blot analysis in MDA-MB-468 breast cancer and SW480 colon cancer cells previously cultured under physiologic (5.5 mM) and diabetogenic (11 mM) glucose concentrations (without and with 100 ng/ml insulin). We studied the culture effects on proliferation and migration of these cells, especially after inhibiting Akt and PLCγ. We found that Akt expression was up-regulated with high glucose and insulin in both cell lines, whereas PLCγ expression was enhanced in colon cancer cells only. High levels of glucose and insulin increased cell proliferation and migration in both cell lines in vitro, mediated by Akt and PLCγ, as shown through the specific pharmacological inhibitors A6730 and U73122.

Conclusions

Our molecular data explain glucose- and insulin-induced changes in a cancer cell and help to understand what might trigger tumor cell proliferation and migration in DM2 patients, too.

【 授权许可】

   
2012 Tomas et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127(12):2893-2917.
• [2]Gupta GP, Massague J: Cancer metastasis: building a framework. Cell 2006, 127(4):679-695.
• [3]Ness-Abramof R, Nabriski D, Apovian CM: Medical therapy for obesity: present and future. Isr Med Assoc J 2004, 6(12):760-765.
• [4]Rapp K, Schroeder J, Klenk J, Ulmer H, Concin H, Diem G, Oberaigner W, Weiland SK: Fasting blood glucose and cancer risk in a cohort of more than 140,000 adults in Austria. Diabetologia 2006, 49(5):945-952.
• [5]LeRoith D, Novosyadlyy R, Gallagher EJ, Lann D, Vijayakumar A, Yakar S: Obesity and type 2 diabetes are associated with an increased risk of developing cancer and a worse prognosis; epidemiological and mechanistic evidence. Exp Clin Endocrinol Diabetes 2008, 116(Suppl 1):S4-S6.
• [6]Giovannucci E, Michaud D: The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology 2007, 132(6):2208-2225.
• [7]Pischon T, Nothlings U, Boeing H: Obesity and cancer. Proc Nutr Soc 2008, 67(2):128-145.
• [8]Schiel R, Beltschikow W, Steiner T, Stein G: Diabetes, insulin, and risk of cancer. Methods Find Exp Clin Pharmacol 2006, 28(3):169-175.
• [9]Del Giudice ME, Fantus IG, Ezzat S, McKeown-Eyssen G, Page D, Goodwin PJ: Insulin and related factors in premenopausal breast cancer risk. Breast Cancer Res Treat 1998, 47(2):111-120.
• [10]Schoen RE, Tangen CM, Kuller LH, Burke GL, Cushman M, Tracy RP, Dobs A, Savage PJ: Increased blood glucose and insulin, body size, and incident colorectal cancer. J Natl Cancer Inst 1999, 91(13):1147-1154.
• [11]Frasca F, Pandini G, Sciacca L, Pezzino V, Squatrito S, Belfiore A, Vigneri R: The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch Physiol Biochem 2008, 114(1):23-37.
• [12]Belfiore A, Frasca F: IGF and insulin receptor signaling in breast cancer. J Mammary Gland Biol Neoplasia 2008, 13(4):381-406.
• [13]Beckner ME, Stracke ML, Liotta LA, Schiffmann E: Glycolysis as primary energy source in tumor cell chemotaxis. J Natl Cancer Inst 1990, 82(23):1836-1840.
• [14]Stracke ML, Kohn EC, Aznavoorian SA, Wilson LL, Salomon D, Krutzsch HC, Liotta LA, Schiffmann E: Insulin-like growth factors stimulate chemotaxis in human melanoma cells. Biochem Biophys Res Commun 1988, 153(3):1076-1083.
• [15]Cheng JQ, Ruggeri B, Klein WM, Sonoda G, Altomare DA, Watson DK, Testa JR: Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci U S A 1996, 93(8):3636-3641.
• [16]Bellacosa A, de Feo D, Godwin AK, Bell DW, Cheng JQ, Altomare DA, Wan M, Dubeau L, Scambia G, Masciullo V, Ferrandina G, Benedetti Panici P, Mancuso S, Neri G, Testa JR: Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer 1995, 64(4):280-285.
• [17]Nicholson KM, Anderson NG: The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 2002, 14(5):381-395.
• [18]Song G, Ouyang G, Bao S: The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 2005, 9(1):59-71.
• [19]Dudek H, Datta SR, Franke TF, Birnbaum MJ, Yao R, Cooper GM, Segal RA, Kaplan DR, Greenberg ME: Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science (New York, NY) 1997, 275(5300):661-665.
• [20]Chen J, Somanath PR, Razorenova O, Chen WS, Hay N, Bornstein P, Byzova TV: Akt1 regulates pathological angiogenesis, vascular maturation and permeability in vivo. Nat Med 2005, 11(11):1188-1196.
• [21]Zhao Z, Leister WH, Robinson RG, Barnett SF, Defeo-Jones D, Jones RE, Hartman GD, Huff JR, Huber HE, Duggan ME, Lindsley CW: Discovery of 2,3,5-trisubstituted pyridine derivatives as potent Akt1 and Akt2 dual inhibitors. Bioorg Med Chem Lett 2005, 15(4):905-909.
• [22]Yamazaki H, Zawalich KC, Zawalich WS: Physiologic implications of phosphoinositides and phospholipase C in the regulation of insulin secretion. J Nutr Sci Vitaminol 2010, 56(1):1-8.
• [23]Sala G, Dituri F, Raimondi C, Previdi S, Maffucci T, Mazzoletti M, Rossi C, Iezzi M, Lattanzio R, Piantelli M, Iacobelli S, Broggini M, Falasca M: Phospholipase Cgamma1 is required for metastasis development and progression. Cancer Res 2008, 68(24):10187-10196.
• [24]Noh DY, Lee YH, Kim SS, Kim YI, Ryu SH, Suh PG, Park JG: Elevated content of phospholipase C-gamma 1 in colorectal cancer tissues. Cancer 1994, 73(1):36-41.
• [25]Thompson AK, Mostafapour SP, Denlinger LC, Bleasdale JE, Fisher SK: The aminosteroid U-73122 inhibits muscarinic receptor sequestration and phosphoinositide hydrolysis in SK-N-SH neuroblastoma cells. A role for Gp in receptor compartmentation. J Biol Chem 1991, 266(35):23856-23862.
• [26]Entschladen F, Niggemann B, Zanker KS, Friedl P: Differential requirement of protein tyrosine kinases and protein kinase C in the regulation of T cell locomotion in three-dimensional collagen matrices. J Immunol 1997, 159(7):3203-3210.
• [27]Niggemann B, Drell TLt, Joseph J, Weidt C, Lang K, Zaenker KS, Entschladen F: Tumor cell locomotion: differential dynamics of spontaneous and induced migration in a 3D collagen matrix. Exp Cell Res 2004, 298(1):178-187.
• [28]Masur K, Vetter C, Hinz A, Tomas N, Henrich H, Niggemann B, Zanker KS: Diabetogenic glucose and insulin concentrations modulate transcriptome and protein levels involved in tumour cell migration, adhesion and proliferation. Br J Cancer 2010, 104(2):345-352.
• [29]Masur K, Lang K, Niggemann B, Zanker KS, Entschladen F: High PKC alpha and low E-cadherin expression contribute to high migratory activity of colon carcinoma cells. Mol Biol Cell 2001, 12(7):1973-1982.
• [30]Robey RB, Hay N: Is Akt the "Warburg kinase"?-Akt-energy metabolism interactions and oncogenesis. Semin Cancer Biol 2009, 19(1):25-31.
• [31]Wang Z, Yang J, Fisher T, Xiao H, Jiang Y, Yang C: Akt Activation is Responsible for Enhanced Migratory and Invasive Behavior of Arsenic-Transformed Human Bronchial Epithelial Cells. Environ Health Perspect 2011,  : .
• [32]Saji M, Narahara K, McCarty SK, Vasko VV, La Perle KM, Porter K, Jarjoura D, Lu C, Cheng SY, Ringel MD: Akt1 deficiency delays tumor progression, vascular invasion, and distant metastasis in a murine model of thyroid cancer. Oncogene 2011,  : .
• [33]Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, Zhuang H, Cinalli RM, Alavi A, Rudin CM, Thompson CB: Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 2004, 64(11):3892-3899.
• [34]Johnson SM, Gulhati P, Rampy BA, Han Y, Rychahou PG, Doan HQ, Weiss HL, Evers BM: Novel expression patterns of PI3K/Akt/mTOR signaling pathway components in colorectal cancer. J Am Coll Surg 2010, 210(5):767-776. 776–768
• [35]Bertrand L, Horman S, Beauloye C, Vanoverschelde JL: Insulin signalling in the heart. Cardiovasc Res 2008, 79(2):238-248.
• [36]Franke TF, Kaplan DR, Cantley LC, Toker A: Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. Science (New York, NY) 1997, 275(5300):665-668.
• [37]Hemkens LG, Grouven U, Bender R, Gunster C, Gutschmidt S, Selke GW, Sawicki PT: Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009, 52(9):1732-1744.
• [38]Baur DM, Klotsche J, Hamnvik OP, Sievers C, Pieper L, Wittchen HU, Stalla GK, Schmid RM, Kales SN, Mantzoros CS: Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort. Metabolism 2010, 60(10):1363-1371.